Nucleic acid constructs for expressing polypeptides in cells
AssigneeQuell Therapeutics Limited
InventorJenny MCGOVERN
Life of this patent
Estimating the term…
Abstract
Provided herein is a nucleic acid molecule comprising 5′ to 3′ a first nucleotide sequence encoding a safety switch polypeptide comprising a suicide moiety; a second nucleotide sequence encoding FOXP3; and a third nucleotide sequence encoding a chimeric antigen receptor (CAR); particularly wherein said first, second, and third nucleotide sequences are separated by nucleotide sequences encoding self-cleavage sequences. Also provided are constructs, vectors and cells comprising the nucleic acid molecule, and methods and uses for expressing the encoded polypeptides in cells, particularly in immune cells useful in adoptive cell therapy (ACT).
Claims30
An expression construct comprising a nucleic acid molecule comprising 5′ to 3′:
- (i) a first nucleotide sequence encoding a safety switch polypeptide comprising a suicide moiety;
- (ii) a second nucleotide sequence encoding FOXP3;
- and
- (iii) a third nucleotide sequence encoding a chimeric antigen receptor (CAR);
- wherein said first, second, and third nucleotide sequences are operably linked to an SFFV promoter.
3-8. (canceled)
10-17. (canceled)
19-20. (canceled)
(canceled)
25-26. (canceled)
31-32. (canceled)
(canceled)
(canceled)
The method according to claim 32, wherein the autoimmune or allergic disease is selected from inflammatory skin diseases including psoriasis and dermatitis;
- responses associated with inflammatory bowel disease, including Crohn's disease and ulcerative colitis;
- dermatitis;
- allergic conditions including food allergy, eczema and asthma;
- rheumatoid arthritis;
- systemic lupus erythematosus (SLE) including lupus nephritis and cutaneous lupus;
- diabetes mellitus including type 1 diabetes mellitus or insulin dependent diabetes mellitus;
- CIPD, multiple sclerosis, neurodegenerative diseases including. ALS;
- and juvenile onset diabetes.
(canceled)
42-44. (canceled)
A method of increasing the sensitivity of a cell expressing a safety switch polypeptide comprising a suicide moiety of at least one CD20 epitope recognised by Rituximab, to Rituximab, comprising introducing into said cell a nucleic acid molecule comprising a nucleotide sequence encoding said safety switch polypeptide wherein said nucleotide sequence is operably linked to a SFFV promoter.
(canceled)
Dependencies are inferred from the claim text.